|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:appointed_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:1982
gptkb:FDA
|
|
gptkbp:clinical_trial
|
diabetes management
insulin therapy
blood glucose control
diabetes management studies
insulin therapy studies
|
|
gptkbp:contraindication
|
severe hypoglycemia
hypersensitivity to insulin
|
|
gptkbp:form
|
gptkb:Humulin_70/30
gptkb:Humulin_N
gptkb:Humulin_R
|
|
gptkbp:formulation
|
gptkb:printer
gptkb:tablet
vial
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Humulin
|
|
gptkbp:ingredients
|
insulin human
|
|
gptkbp:interacts_with
|
diuretics
beta-blockers
thiazolidinediones
|
|
gptkbp:invention
|
patented
generic available
|
|
gptkbp:is_used_for
|
gptkb:Company
|
|
gptkbp:manager
|
intravenous
subcutaneous
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
duration of action 5-8 hours
onset of action 30 minutes
peak action 2-5 hours
|
|
gptkbp:population
|
gptkb:Type_1_diabetes
Type 2 diabetes
|
|
gptkbp:products
|
gptkb:Lantus
gptkb:Novolog
gptkb:Toujeo
gptkb:Levemir
gptkb:Tresiba
|
|
gptkbp:provides_information_on
|
ADA Standards of Medical Care
AACE Diabetes Management Guidelines
|
|
gptkbp:safety_features
|
monitor blood glucose
adjust dosage as needed
dispose of needles properly
do not share pens
watch for signs of hypoglycemia
|
|
gptkbp:side_effect
|
weight gain
injection site reactions
hypoglycemia
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:type
|
gptkb:recombinant_human_insulin
|
|
gptkbp:bfsParent
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
3
|